Literature DB >> 24312780

Modified synthesis of erlotinib hydrochloride.

Leila Barghi1, Ayuob Aghanejad, Hadi Valizadeh, Jaleh Barar, Davoud Asgari.   

Abstract

PURPOSE: An improved and economical method has been described for the synthesis of erlotinib hydrochloride, as a useful drug in treatment of non-small-cell lung cancer.
METHOD: Erlotinib hydrochloride was synthesized in seven steps starting from 3, 4-dihydroxy benzoic acid. In this study, we were able to modify one of the key steps which involved the reduction of the 6-nitrobenzoic acid derivative to 6-aminobenzoic acid derivative. An inexpensive reagent such as ammonium formate was used as an in situ hydrogen donor in the presence of palladium/charcoal (Pd/C) instead of hydrogen gas at high pressure. RESULT: This proposed method proceeded with 92% yield at room temperature. Synthesis of erlotinib was completed in 7 steps with overall yield of 44%.
CONCLUSION: From the results obtained it can be concluded that the modified method eliminated the potential danger associated with the use of hydrogen gas in the presence of flammable catalysts. It should be mentioned that the catalyst was recovered after the reaction and could be used again.

Entities:  

Keywords:  Erlotinib; Palladium/Charcoal (Pd/C); Tyrosine kinase

Year:  2012        PMID: 24312780      PMCID: PMC3846011          DOI: 10.5681/apb.2012.017

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  6 in total

1.  One-pot reductive mono-N-alkylation of aniline and nitroarene derivatives using aldehydes.

Authors:  Eunyoung Byun; Bomi Hong; Kathlia A De Castro; Minkyung Lim; Hakjune Rhee
Journal:  J Org Chem       Date:  2007-11-13       Impact factor: 4.354

Review 2.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

Review 3.  Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.

Authors:  Janine Smith
Journal:  Clin Ther       Date:  2005-10       Impact factor: 3.393

4.  Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  Erin R Lepper; Sandra M Swain; Antoinette R Tan; William D Figg; Alex Sparreboom
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-10-25       Impact factor: 3.205

Review 5.  Molecular targets in cancer therapy.

Authors:  Danielle M Gale
Journal:  Semin Oncol Nurs       Date:  2003-08       Impact factor: 2.315

6.  Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.

Authors:  Venkateshappa Chandregowda; A K Kush; G Chandrasekara Reddy
Journal:  Eur J Med Chem       Date:  2008-07-26       Impact factor: 6.514

  6 in total
  3 in total

1.  Development and application of an HPLC method for erlotinib protein binding studies.

Authors:  Soheila Bolandnazar; Adeleh Divsalar; Hadi Valizadeh; Arash Khodaei; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 2.  Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.

Authors:  Mohammed A S Abourehab; Alaa M Alqahtani; Bahaa G M Youssif; Ahmed M Gouda
Journal:  Molecules       Date:  2021-11-04       Impact factor: 4.411

3.  Dissolution improvement of binary solid dispersions of erlotinib prepared by one-step electrospray method.

Authors:  Azin Jahangiri; Fakhronnesa Khalilzad; Leila Barghi
Journal:  Biol Methods Protoc       Date:  2022-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.